Product Information
CETIRIZINE HCL 5 MG TABLET is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $0.0476 per EA under NDC 00378363501. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Dec 27, 2007.
Strength
5 mg/1
Manufacturer
Mylan Pharmaceuticals Inc.NDC
00378363501
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CETIRIZINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA076677FDA Approved
12/27/2007
On Market Since
12/27/2007
Pharmacological Classes
Price Statistics
The NADAC for CETIRIZINE HCL 5 MG TABLET has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 27.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0476 per EA |
|---|---|
| All-time high | $0.0858 (Nov 13, 2019) |
| All-time low | $0.0382 (Nov 20, 2024) |
| 52-week high | $0.0526 |
| 52-week low | $0.0472 |
| Median price | $0.0556 |
| Average price | $0.0566 |
| Largest weekly change | +48.6% (May 22, 2019) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the cetirizine hydrochloride market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mylan Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
cetirizine hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Histamine-1 Receptor Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CETIRIZINE HCL 5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for CETIRIZINE HCL 5 MG TABLET, manufactured by Mylan Pharmaceuticals Inc., is $0.0476 per EA (NDC 00378363501), effective Sep 30, 2026.
How has the price of CETIRIZINE HCL 5 MG TABLET changed over time?
Over the history we have for it, the NADAC for CETIRIZINE HCL 5 MG TABLET has declined 27.9%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for CETIRIZINE HCL 5 MG TABLET?
Since Nov 28, 2013, the NADAC for CETIRIZINE HCL 5 MG TABLET has ranged from a low of $0.0382 (Nov 20, 2024) to a high of $0.0858 (Nov 13, 2019), with a median of $0.0556 per EA.
Are there cheaper alternatives to CETIRIZINE HCL 5 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of CETIRIZINE HCL 5 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures CETIRIZINE HCL 5 MG TABLET?
CETIRIZINE HCL 5 MG TABLET (NDC 00378363501) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.